C
Cardiff Oncology, Inc. (CRDF)
NCM – Real vaqt narxi. Valyuta: USD
1.64
+0.01 (0.61%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
1.64
+0.01 (0.61%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Cardiff Oncology, Inc., klinik bosqichdagi biotexnologiya kompaniyasi bo'lib, Qo'shma Shtatlarda turli xil saraton turlarini davolash uchun yangi usullarni ishlab chiqadi. Uning asosiy dori nomzodi Onvansertib bo'lib, bu RAS mutatsiyasi bo'lgan metastatik kolorektal saratonni davolash uchun og'iz orqali qabul qilinadigan va selektiv polo-like kinase 1 inhibitoridir. Kompaniya shuningdek, metastatik oshqozon osti bezi oqimi adenokarsinomasi, mayda hujayrali o'pka rakki, metastatik uchlik salbiy ko'krak bezi rakki va surunkali miyelomonotsitar leykemiya kabi ko'rsatmalarga oid klinik dasturga e'tibor qaratadi; CRDF-004, KRAS yoki NRAS mutatsiyasiga ega bo'lgan bemorlarda tasdiqlangan metastatik va operatsiya qilinmaydigan kolorektal saratonni davolash uchun FOLFIRI va bevacizumab yoki FOLFOX va bevacizumab bilan birgalikda onvansertibni tekshiruvchi 2-bosqichli ochiq-label randomizatsiyalangan ko'p markazli klinik tadqiqot; va TROV-054, KRAS mutatsiyasi bo'lgan metastatik kolorektal saratonni tekshiruvchi 1b/2 fazali bir guruhli klinik tadqiqot. Kompaniya ilgari Trovagene, Inc. nomi bilan tanilgan va 2012 yil may oyida Cardiff Oncology, Inc. deb o'zgartirgan. Cardiff Oncology, Inc. 1999 yilda tashkil etilgan va shtab-kvartirasi San-Diego, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Ajay Aggarwal M.B.A., M.D. | Chief Operating Officer |
| Dr. Mani Mohindru Ph.D. | President, CEO & Director |
| Dr. Roger Sidhu FRCPC, M.D. | Chief Medical Officer |
| Dr. Tod Smeal Ph.D. | Chief Scientific Officer |
| Mr. Josh Muntner BFA, M.B.A. | Chief Financial Officer |
| Ms. Brigitte Lindsay | Chief Accounting Officer |
| Ms. Elizabeth Anderson | VP of Finance & Administration |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-23 | DEF 14A | crdf-20260423.htm |
| 2026-04-09 | 8-K | crdf-20260406.htm |
| 2026-04-02 | 8-K | crdf-20260327.htm |
| 2026-02-25 | 8-K | crdf-20260225.htm |
| 2026-02-24 | 8-K | crdf-20260224.htm |
| 2026-02-24 | 10-K | crdf-20251231.htm |
| 2026-01-27 | 8-K | crdf-20260127.htm |
| 2025-11-06 | 8-K | crdf-20251106.htm |
| 2025-08-28 | S-8 | crdf-20250828.htm |
| 2025-07-29 | 8-K | crdf-20250729.htm |